This week in therapeutics




Licensing status

Publication and contact ­information

Infectious disease


HIV gp120; CD4

Ex vivo tissue and nonhuman primate studies suggest topical formulations of miniCD4 could be used to prevent HIV infection. miniCD4 is a CD4 mimetic that is built into a stabilizing 27-amino-acid scaffold and interacts with the CD4-binding site of HIV gp120. In human cervical or colorectal human tissue explants, pretreatment with the miniCD4 topical microbicide prevented infection of the tissues. In a macaque model of SIV infection, vaginal pretreatment with the miniCD4 microbicide one hour before high-dose challenge prevented infection in five out of six animals. Next steps include toxicology studies of the miniCD4 microbicide.

SciBX 5(49); doi:10.1038/scibx.2012.1284
Published online Dec. 20, 2012

MiniCD4 peptides patented; available for licensing

Dereuddre-Bosquet, N. et al. PLoS Pathog.; published online Dec. 6, 2012;
Contact: Loïc Martin, Institute of Biology and Technology Saclay, Gif sur Yvette, France